港股异动丨再鼎医药-SB(9688.HK)低开逾4% 一季度净亏损扩大至2.3亿美元
格隆汇5月11日丨再鼎医药-SB(09688.HK)低开逾4%,报1170港元,总市值1030亿港元。再鼎医药昨晚宣布,截至2021年3月31日止3个月,公司产品净收入为2,010万美元,2020年同期收入为820万美元。其中包括则乐销售收入1,260万美元(2020年同期为630万美元)和爱普盾销售收入710万美元(2020年同期为190万美元)。期间再鼎医药亏损净额为2.329亿美元,2020年同期的亏损净额为4,800万美元。亏损净额的增加主要由于与argenx和Turning point的战略合作相关付款,均记为研发费用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.